Cargando…

Advances in the management of uterine fibroids

Uterine fibroids are extremely common, with major surgery the current main management option; uterine artery embolisation is an alternative, but risks to fertility are unclear. Minimally invasive procedures are becoming more commonly performed via both the hysteroscope and laparoscope, minimising re...

Descripción completa

Detalles Bibliográficos
Autores principales: Munro, Kirsty I, Critchley, Hilary OD
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948321/
https://www.ncbi.nlm.nih.gov/pubmed/20948705
http://dx.doi.org/10.3410/M1-74
_version_ 1782187445963456512
author Munro, Kirsty I
Critchley, Hilary OD
author_facet Munro, Kirsty I
Critchley, Hilary OD
author_sort Munro, Kirsty I
collection PubMed
description Uterine fibroids are extremely common, with major surgery the current main management option; uterine artery embolisation is an alternative, but risks to fertility are unclear. Minimally invasive procedures are becoming more commonly performed via both the hysteroscope and laparoscope, minimising recovery time for patients. Recently, small doses of progesterone receptor modulators (mifepristone and asoprisnil) have been shown to be effective in reducing menstrual blood loss and fibroid size. Progress from here should include the development of a well-tolerated oral preparation that will maintain fertility.
format Text
id pubmed-2948321
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29483212010-10-14 Advances in the management of uterine fibroids Munro, Kirsty I Critchley, Hilary OD F1000 Med Rep Review Article Uterine fibroids are extremely common, with major surgery the current main management option; uterine artery embolisation is an alternative, but risks to fertility are unclear. Minimally invasive procedures are becoming more commonly performed via both the hysteroscope and laparoscope, minimising recovery time for patients. Recently, small doses of progesterone receptor modulators (mifepristone and asoprisnil) have been shown to be effective in reducing menstrual blood loss and fibroid size. Progress from here should include the development of a well-tolerated oral preparation that will maintain fertility. Medicine Reports Ltd 2009-09-28 /pmc/articles/PMC2948321/ /pubmed/20948705 http://dx.doi.org/10.3410/M1-74 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Munro, Kirsty I
Critchley, Hilary OD
Advances in the management of uterine fibroids
title Advances in the management of uterine fibroids
title_full Advances in the management of uterine fibroids
title_fullStr Advances in the management of uterine fibroids
title_full_unstemmed Advances in the management of uterine fibroids
title_short Advances in the management of uterine fibroids
title_sort advances in the management of uterine fibroids
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948321/
https://www.ncbi.nlm.nih.gov/pubmed/20948705
http://dx.doi.org/10.3410/M1-74
work_keys_str_mv AT munrokirstyi advancesinthemanagementofuterinefibroids
AT critchleyhilaryod advancesinthemanagementofuterinefibroids